Ocular Immunology and Inflammation最新文献

{"title":"Disseminated Sporotrichosis with Intraocular Involvement.","authors":"Maria Carolina Francisco Kuba, Lisiane Rísia Pinto Barbosa, Alexandre de Carvalho Mendes Paiva, Dayvison Francis Saraiva Freitas, Maria Clara Gutierrez Galhardo, Ana Luiza Biancardi, André Luiz Land Curi","doi":"10.1080/09273948.2025.2469621","DOIUrl":"https://doi.org/10.1080/09273948.2025.2469621","url":null,"abstract":"<p><strong>Purpose: </strong>To report a rare case of intraocular sporotrichosis in a patient with disseminated sporotrichosis and a consumptive syndrome possibly secondary to multiple myeloma.</p><p><strong>Material and methods: </strong>Case report.</p><p><strong>Results: </strong>A 55-year-old male patient with consumptive syndrome and a history of alcoholism presented to the uveitis clinic complaining of decreased visual acuity in the right eye (RE), accompanied by ocular pain and hyperemia. He had disseminated sporotrichosis and was undergoing treatment with itraconazole 400 mg/day. Ophthalmologic examination revealed visual acuity of light perception in the RE and 20/30 in the left eye (LE). Slit-lamp biomicroscopy of the RE showed granulomatous keratic precipitates, cells 4+, flare 3+, posterior synechiae, cataract, and a round, yellowish-white lesion in the temporal region of the anterior chamber. Fundoscopy of the RE was not possible due to media opacity, and ultrasonography suggested a vitreous inflammatory process. Aqueous humor culture tested positive for <i>Sporothrix</i> sp. Intracameral and intravitreal injections of amphotericin B were administered, followed by phacoemulsification without intraocular lens implantation, combined with pars plana vitrectomy and an additional intravitreal injection of amphotericin B. At follow-up, visual acuity improved to 20/60, with a reduction of inflammation. The patient remains under investigation for multiple myeloma.</p><p><strong>Conclusion: </strong>Rare manifestations of intraocular sporotrichosis highlight the need to investigate underlying  immunosuppression.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-4"},"PeriodicalIF":2.6,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral Neuroretinitis Following Treatment with Sofosbuvir and Velpatasvir.","authors":"Hitesh Sharma, Jaydeep Walinjkar, Parthopratim Dutta Majumder","doi":"10.1080/09273948.2025.2470902","DOIUrl":"https://doi.org/10.1080/09273948.2025.2470902","url":null,"abstract":"<p><strong>Purpose: </strong>We report a case of bilateral neuroretinitis like picture following ingestion of Direct Acting Antivirals (DAAs) in the form of sofosbuvir and velpatasvir, for treatment of Chronic Hepatitis C infection.</p><p><strong>Methods: </strong>retrospective observational case report and review of literature.</p><p><strong>Results: </strong>A healthy 49 years old male, known case of Chronic heptatis C; developed bilateral painless diminution of vision following treatment with DAAs-sofosbuvir and velpatasvir-for treatment-naïve hepatitis C. After thorough work up, ruling out other causes and stopping of medications there was complete resolution of the lesions.</p><p><strong>Conclusion: </strong>Ocular side effects of Direct Acting Antivirals (DAAs) for treatment of Chronic Hepatitis C should be considered, as these are now standard care of treatment for the same.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-3"},"PeriodicalIF":2.6,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social Determinants of Health in Uveitis: A Literature Review.","authors":"Annie Zhang, Paulina Liberman, Meghan K Berkenstock","doi":"10.1080/09273948.2025.2465774","DOIUrl":"https://doi.org/10.1080/09273948.2025.2465774","url":null,"abstract":"<p><strong>Background: </strong>The uveitides are a group of intraocular inflammatory diseases which can lead to blindness without treatment. It has been shown that socioeconomic status, health literacy, and access to healthcare play a pivotal role in the prevalence, severity, and treatment outcomes in ophthalmic conditions. We review the current literature on the impact of social determinants of health (SDoH) in patients with uveitis.</p><p><strong>Methods: </strong>A systematic literature search was conducted utilizing PubMed, Google Scholar, and Embase databases in July 2024. Inclusion criteria included studies written in English, focusing on SDoH in patients with uveitis using the following keywords: \"uveitis,\" \"social determinants of health,\" \"socioeconomic status,\" \"education,\" \"access to healthcare,\" \"health literacy,\" \"health disparities,\" \"race/ethnicity,\" \"gender,\" and \"environmental factors.\" Case reports were excluded.</p><p><strong>Results: </strong>Fifty two articles were included. Among these, 31 addressed healthcare access (e.g. limited specialist availability, cost/insurance barriers, urban-rural gaps), 23 highlighted economic stability (e.g. low income, out-of-pocket costs, poor medication adherence), 19 discussed environment and community (e.g. higher infectious uveitis rates in resource-limited areas, lack of social support), 18 focused on racial and ethnic disparities (e.g. advanced disease at presentation, worse outcomes for African American, Hispanic, and Indigenous populations), and 15 addressed education and awareness (e.g. low health literacy, inadequate patient education materials). Nine papers examined two domains, and 10 incorporated three or more. Across domains, limited resources and knowledge were associated with delayed diagnosis, suboptimal adherence, and poorer visual outcomes.</p><p><strong>Conclusion: </strong>The current literature shows a correlation between SDoH and an increased incidence and poorer disease outcomes in patients with uveitis. Further research is needed to mitigate disparities in care for patients with uveitis.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-10"},"PeriodicalIF":2.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological Characterization of Uveitis in Japan: a Systematic Review.","authors":"Tom Liba, Alon Gorenshtein, Liron Leibovitch, Raz Gepstein, Elcio Machinski, Ori Segal","doi":"10.1080/09273948.2025.2452193","DOIUrl":"https://doi.org/10.1080/09273948.2025.2452193","url":null,"abstract":"<p><strong>Purpose: </strong>Study the etiologies, behind uveitis, examine the anatomical location, and explore how these causes vary across regions in Japan.</p><p><strong>Methods: </strong>The systemic review was conducted followed the PRISMA guidelines, searching through databases, like PubMed/MEDLINE, Scopus, Central and Web of Science, from January 1990 to August 2024. Our focus was on studies done in Japan. Presented in either English or Japanese and provided information on uveitis etiologies. We excluded any studies using selfreported data during our selection process.</p><p><strong>Results: </strong>Out of a total of 1,738 studies initially considered, only 20 met the criteria for inclusion. The majority of uveitis cases were categorized as \"unclassified.\" Sarcoidosis was the most common systemic etiology, followed by VogtKoyanagiHarada (VKH), with Behcet's disease coming next. Most studies showed a greater number of female patients. In Tokyo, sarcoidosis accounts for 8.9% of uveitis cases, making it the most systemic association cause. In contrast, in Hokkaido, while sarcoidosis remains the leading systemic association of uveitis, it is significantly more prevalent at 19.5%.</p><p><strong>Conclusion: </strong>The findings reveal significant regional variations in the causes of uveitis across Japan, with sarcoidosis playing a major role. These regional differences underscore the importance of considering local factors in the diagnosis and treatment of uveitis. Additionally, the high prevalence of unclassified uveitis cases points to the urgent need for better methods to accurately identify and manage these conditions.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-10"},"PeriodicalIF":2.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Depression in Non-Infectious Uveitis Patients in a Tertiary Care Center in Lebanon.","authors":"Rami Abdul-Halim, Mahdi M Hassoun, Farid Talih, Housein H Zeaiter, Jana Tabaja, Chadi Antoun, Rola N Hamam","doi":"10.1080/09273948.2025.2469605","DOIUrl":"https://doi.org/10.1080/09273948.2025.2469605","url":null,"abstract":"<p><strong>Purpose: </strong>Depression is a significant burden for uveitis patients due to the chronic nature of their condition and associated vision impairment. Non-infectious uveitis (NIU), often linked to autoimmune diseases, frequently involves psychological distress. This study examines depression prevalence among NIU patients in Lebanon to address gaps in regional data.</p><p><strong>Methods: </strong>This cross-sectional study recruited 100 NIU patients and 100 controls from a tertiary care center in Lebanon. Depression was assessed using the Patient Health Questionnaire-2 (PHQ-2) and confirmed with the Patient Health Questionnaire-9 (PHQ-9) for positive screens. Demographics, disease characteristics, and treatment data were extracted from medical records. Statistical analyses included independent t-tests and multivariate analysis (<i>p</i> < 0.05).</p><p><strong>Results: </strong>Depression prevalence was 35% in NIU patients versus 26% in controls, though not statistically significant (<i>p</i> = 0.167). Corticosteroid usage correlated with higher depression risk (OR = 3.85 [95% CI: 1.33,11.2], <i>p</i> = 0.013), while longer uveitis duration correlated with lower depression risk (OR = 0.93 [95% CI: 0.89, 0.97], <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Depression is prevalent among NIU patients in Lebanon, particularly females and vulnerable demographics. Integrated care strategies addressing mental health within ophthalmology practices are essential to improve quality of life. Future research should explore additional psychological conditions and contributing factors.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-6"},"PeriodicalIF":2.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcomes of Uveoretinitis in Behçet's Disease in the Era of Biologic Treatments: A 10-Year Follow-Up Study.","authors":"Risa Sugawara, Yoshihiko Usui, Kinya Tsubota, Hiroshi Goto","doi":"10.1080/09273948.2025.2467435","DOIUrl":"https://doi.org/10.1080/09273948.2025.2467435","url":null,"abstract":"<p><strong>Purpose: </strong>Treatment with biologics such as infliximab (IFX) for Behçet's Disease (BD) with uveoretinitis refractory to other existing therapies is well established. However, although some patients have maintained or improved their vision with IFX, other patients can manage without biologics. In this study, we investigated the demographics, clinical features, treatment of uveoretinitis, and outcomes of patients with BD uveoretinitis who were followed long-term with or without treatment with biologics.</p><p><strong>Methods: </strong>This study included 38 patients diagnosed with BD uveoretinitis followed for more than 10 years since treatment initiation. Using data extracted from medical records, we evaluated best-corrected visual acuity, medical and surgical treatments, Behçet's Disease Ocular Attack Score 24 (BOS24), and extraocular symptoms during observation for more than 10 years.</p><p><strong>Results: </strong>The mean BCVA was 0.25 logMAR at the first visit and 0.33 logMAR after 10-year follow-up, with no significant difference. Biologics were initiated in one-half of the patients, while the other half were managed with colchicine or steroid eye drops alone. The mean BCVA remained stable at 0.33 logMAR in patients treated with biologics, and changed from 0.17±0.33 to 0.32±0.60 logMAR in those untreated with biologics. Both groups showed improvements in ocular inflammatory attacks and extraocular symptoms over 10 years.</p><p><strong>Conclusion: </strong>While biologic therapies, particularly TNF inhibitors, play an important role in managing refractory cases of BD uveoretinitis, our study suggests that conventional therapies such as colchicine may also provide effective long-term disease control. This highlights the importance of individualized treatment decisions, factoring in both medical and economic considerations.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-7"},"PeriodicalIF":2.6,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Corticosteroids Combined with 15 Mg/Week Methotrexate as Initial Treatment for Acute Vogt-Koyanagi-Harada Disease.","authors":"Yao Lu, Yuan Pan, Yuxi Chen, Xiaoqing Chen, Yanyan Xie, Yiwen Xia, Dan Liang","doi":"10.1080/09273948.2025.2464716","DOIUrl":"https://doi.org/10.1080/09273948.2025.2464716","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the efficacy and safety of initial treatment combining corticosteroids and 15 mg/week methotrexate (MTX) for acute Vogt-Koyanagi-Harada disease (VKH).</p><p><strong>Methods: </strong>A retrospective, longitudinal observational case series was conducted. Newly onset VKH patients received corticosteroids combining 15 mg/week MTX, and follow-up period ≥ 6 months were consecutively enrolled. Main outcome measures were the corticosteroid-sparing effect, improvements of visual function, changes of ophthalmic characteristics and recurrences.</p><p><strong>Results: </strong>In this case series, 39 acute VKH patients (78 eyes) received corticosteroids combining oral MTX as first-line therapy. All the participants achieved corticosteroid-sparing effect and thereafter withdrew corticosteroids. At the last follow-up, 87.2% patients had managed to discontinue MTX. The median period of corticosteroids treatment was 9.2 (8.0-13.3) months, and the mean interval of MTX using was 18.0 ± 6.1 months. Eventually, 83.3% of eyes achieved visual acuity of 0.0 logMAR or better. All the eyes had retinal reattachment and the choroidal thickness significantly decreased. Sun-set glow fundus was identified in 18 eyes (23.1%). The microvascular perfusion was still defect despite the well-controlled inflammation. Recurrence occurred in five patients, with only one progressing to a chronic recurrent stage. No severe adverse event was observed.</p><p><strong>Conclusion: </strong>Initial treatments with corticosteroids tapered over approximately 9 months and oral methotrexate (15 mg/week) for 18 months in acute VKH patients led to favorable visual outcomes, fairly low recurrence and good safety profile. These findings support the consideration of this combined treatment for acute VKH but should be tempered by recognizing the retrospective and non-control design.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-8"},"PeriodicalIF":2.6,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular Manifestations of Psoriasis: A Systematic Review.","authors":"Atheer G Almutairi, Leena I Aloraini, Rahaf R Almutairi, Alanoud A Alfaqih, Shahad A Alruwaili, Sara Aljefri","doi":"10.1080/09273948.2025.2459710","DOIUrl":"https://doi.org/10.1080/09273948.2025.2459710","url":null,"abstract":"<p><strong>Purpose: </strong>Psoriasis, a chronic inflammatory skin disease, manifests itself by an array of immunological and inflammatory alterations. Ocular involvement can occur through a variety of pathways, notably direct interaction with psoriatic plaques or psoriasis-associated inflammatory responses. The present systematic review was intended to more effectively comprehend and describe the prevalent nature of psoriasis ocular symptoms by tracking all relevant studies published over the last decade and carefully synthesizing their findings.</p><p><strong>Methods: </strong>This systematic review was performed by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for study selection, synthesis, and reporting of results. The PubMed, Cochrane, and Scopus databases were used to search for evidence-based research papers on psoriasis ocular symptoms published between January 2012 and August 2023.</p><p><strong>Results: </strong>The prevalence of ocular manifestations in psoriasis varied between the studies ranging from 81.4% to 10%. The increase in the ocular symptoms with prolonged duration of psoriasis was statistically significant. Dry eye condition is the most prevalent clinical ocular alteration related to psoriasis. Blepharitis, conjunctivitis, keratopathy, and uveitis were common in psoriasis patients. Higher intraocular pressure and glaucoma were reported.</p><p><strong>Conclusion: </strong>Physicians should keep in mind and look for ocular associations in Psoriasis patients. Addressing the crucial stages in the pathophysiology of ocular alterations is essential for targeted efforts for immunotherapeutic management. Interventions are shifting away from broad immunosuppression towards the administration of particular biologicals that target specific components of the immune response.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-9"},"PeriodicalIF":2.6,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Retinal Necrosis: A Multicenter Study on Factors Associated with Visual Outcomes and Retinal Detachment.","authors":"Panuwat Soitong, Yaninsiri Ngathaweesuk, Noppakhun Panyayingyong, Atchara Amphornphruet, Variya Nganthavee, Boonsub Sakboonyarat, Narumon Keorochana","doi":"10.1080/09273948.2025.2464717","DOIUrl":"https://doi.org/10.1080/09273948.2025.2464717","url":null,"abstract":"<p><strong>Purpose: </strong>This multicenter study aimed to evaluate visual outcomes and analyze the specific viral pathogens and other factors associated with severe visual impairment (SVI), and retinal detachment (RD) in patients with acute retinal necrosis (ARN).</p><p><strong>Methods: </strong>A retrospective multicenter cohort study included ARN patients who underwent aqueous or vitreous PCR testing. Multivariable mixed-effects Poisson regression was used to identify factors associated with viral pathogens and SVI. A mixed-effects parametric survival-time model was applied to evaluate RD risk factors.</p><p><strong>Results: </strong>A total of 56 patients (65 eyes) diagnosed with ARN were included. 31 patients (47.7%) had a final visual acuity of 20/200 or worse. SVI was associated with zone 1 involvement (aRR 4.2), immunocompromised status (aRR 2.8), and RD (aRR 4.8). RD occurred in 23 patients (35.4%) after an average of 4.26 months from the onset of ARN. The incidence rate of RD was 1.4 per 1,000 eye-days (95% CI: 0.9-2.1. It increased in VZV-ARN cases by 4.02 times (log-rank <i>p</i> = 0.008), patients with retinitis affecting 2-3 quadrants, and in immunocompetent status.</p><p><strong>Conclusion: </strong>Zone 1 involvement, immunocompromised status, and RD were key risk factors for SVI in ARN. RD occurred in approximately one-third of cases. Early and aggressive intervention is essential in VZV-ARN cases, particularly in cases where retinitis involves 2-3 quadrants of the retina and in immunocompetent individuals, to mitigate the risk of RD.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-8"},"PeriodicalIF":2.6,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Outcomes in Patients with Acute Syphilitic Posterior Placoid Chorioretinitis.","authors":"Eleftherios I Agorogiannis, Usman Rashid, Amira Stylianides, Sasa Pockar, Shiao Wei Wong, Ashish Sukthankar, Nicholas P Jones","doi":"10.1080/09273948.2025.2459677","DOIUrl":"https://doi.org/10.1080/09273948.2025.2459677","url":null,"abstract":"<p><strong>Purpose: </strong>To describe clinical outcomes in a large cohort with acute syphilitic posterior placoid chorioretinitis (ASPPC).</p><p><strong>Methods: </strong>Clinical records of patients with ASPPC, diagnosed between 2012 and 2023, were retrospectively reviewed. Confirmation of syphilis diagnosis required positive serological testing, except in human immunodeficiency virus (HIV)-positive patients. Data collected included demographics and HIV status, baseline and final best corrected visual acuity (BCVA), optical coherence tomography (OCT) and fundus autofluorescence (FAF) imaging at baseline, antimicrobial treatment, and oral corticosteroid use.</p><p><strong>Results: </strong>A total of thirty-five patients (31 male) were included. Recognition of ASPPC led to a diagnosis of syphilis in 32 (91.4%) patients. Eight (22.9%) patients were HIV-positive. A total of fourteen (40.0%) patients presented with bilateral ASPPC. Concurrent retinitis was identified in 4 (8.2%) of 49 affected eyes. All patients manifested typical ASPPC changes on OCT imaging (ellipsoid zone disruption and retinal pigment epithelial thickening and nodular elevations) with corresponding FAF alterations. All received oral prednisolone for 3 days and antimicrobial treatment; a longer course of oral prednisolone was prescribed in 32 (91.4%) patients with median treatment duration of 11 weeks (range 2-65). Median follow-up was 19.5 weeks (range 2-173). Following treatment, mean (±standard deviation) LogMAR BCVA improved from +0.70 (±0.78) to +0.21 (±0.41) (<i>p</i> < 0.0001), whereas anatomical recovery was evident in 37 (84.1%) of 44 eyes with available imaging at final follow-up.</p><p><strong>Conclusion: </strong>In the largest cohort of patients with ASPPC reported to date, combination systemic antimicrobial and corticosteroid treatment was associated with favourable outcomes. Using systemic steroids alongside antibiotics in patients with ASPPC is safe.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-9"},"PeriodicalIF":2.6,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}